These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 36658237)

  • 1. YTHDF2 orchestrates tumor-associated macrophage reprogramming and controls antitumor immunity through CD8
    Ma S; Sun B; Duan S; Han J; Barr T; Zhang J; Bissonnette MB; Kortylewski M; He C; Chen J; Caligiuri MA; Yu J
    Nat Immunol; 2023 Feb; 24(2):255-266. PubMed ID: 36658237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Blocking LTB
    Yan J; Zhu J; Li X; Yang R; Xiao W; Huang C; Zheng C
    Phytomedicine; 2023 Oct; 119():154968. PubMed ID: 37531900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Photosensitive and dual-targeted chromium nanoparticle delivering small interfering RNA YTHDF1 for molecular-targeted immunotherapy in liver cancer.
    Chen S; He Y; Huang X; Shen Y; Zou Q; Yang G; Fu L; Liu Q; Luo D
    J Nanobiotechnology; 2024 Jun; 22(1):348. PubMed ID: 38898486
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multifunctional Redox-Responsive Nanoplatform with Dual Activation of Macrophages and T Cells for Antitumor Immunotherapy.
    Zhang W; Liu X; Cao S; Zhang Q; Chen X; Luo W; Tan J; Xu X; Tian J; Saw PE; Luo B
    ACS Nano; 2023 Aug; 17(15):14424-14441. PubMed ID: 37498878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting OXCT1-mediated ketone metabolism reprograms macrophages to promote antitumor immunity via CD8
    Zhu CX; Yan K; Chen L; Huang RR; Bian ZH; Wei HR; Gu XM; Zhao YY; Liu MC; Suo CX; Li ZK; Yang ZY; Lu MQ; Hua XF; Li L; Zhao ZB; Sun LC; Zhang HF; Gao P; Lian ZX
    J Hepatol; 2024 May; ():. PubMed ID: 38759889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor cell-released autophagosomes (TRAPs) promote immunosuppression through induction of M2-like macrophages with increased expression of PD-L1.
    Wen ZF; Liu H; Gao R; Zhou M; Ma J; Zhang Y; Zhao J; Chen Y; Zhang T; Huang F; Pan N; Zhang J; Fox BA; Hu HM; Wang LX
    J Immunother Cancer; 2018 Dec; 6(1):151. PubMed ID: 30563569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The tumor-intrinsic role of the m
    Xiao S; Ma S; Sun B; Pu W; Duan S; Han J; Hong Y; Zhang J; Peng Y; He C; Yi P; Caligiuri MA; Yu J
    Sci Immunol; 2024 May; 9(95):eadl2171. PubMed ID: 38820140
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SP140 inhibits STAT1 signaling, induces IFN-γ in tumor-associated macrophages, and is a predictive biomarker of immunotherapy response.
    Tanagala KKK; Morin-Baxter J; Carvajal R; Cheema M; Dubey S; Nakagawa H; Yoon A; Cheng YL; Taylor A; Nickerson J; Mintz A; Momen-Heravi F
    J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36600652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hedgehog-induced PD-L1 on tumor-associated macrophages is critical for suppression of tumor-infiltrating CD8+ T cell function.
    Petty AJ; Dai R; Lapalombella R; Baiocchi RA; Benson DM; Li Z; Huang X; Yang Y
    JCI Insight; 2021 Mar; 6(6):. PubMed ID: 33749663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor microenvironment remodeling via targeted depletion of M2-like tumor-associated macrophages for cancer immunotherapy.
    Cao Y; Qiao B; Chen Q; Xie Z; Dou X; Xu L; Ran H; Zhang L; Wang Z
    Acta Biomater; 2023 Apr; 160():239-251. PubMed ID: 36774974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. C1q
    Zhang S; Peng W; Wang H; Xiang X; Ye L; Wei X; Wang Z; Xue Q; Chen L; Su Y; Zhou Q
    J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37604643
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blockade of C5a receptor unleashes tumor-associated macrophage antitumor response and enhances CXCL9-dependent CD8
    Luan X; Lei T; Fang J; Liu X; Fu H; Li Y; Chu W; Jiang P; Tong C; Qi H; Fu Y
    Mol Ther; 2024 Feb; 32(2):469-489. PubMed ID: 38098230
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Engineered Bacterial Biomimetic Vesicles Reprogram Tumor-Associated Macrophages and Remodel Tumor Microenvironment to Promote Innate and Adaptive Antitumor Immune Responses.
    Zheng P; He J; Fu Y; Yang Y; Li S; Duan B; Yang Y; Hu Y; Yang Z; Wang M; Liu Q; Zheng X; Hua L; Li W; Li D; Ding Y; Yang X; Bai H; Long Q; Huang W; Ma Y
    ACS Nano; 2024 Mar; 18(9):6863-6886. PubMed ID: 38386537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exosome-mediated genetic reprogramming of tumor-associated macrophages by exoASO-STAT6 leads to potent monotherapy antitumor activity.
    Kamerkar S; Leng C; Burenkova O; Jang SC; McCoy C; Zhang K; Dooley K; Kasera S; Zi T; Sisó S; Dahlberg W; Sia CL; Patel S; Schmidt K; Economides K; Soos T; Burzyn D; Sathyanarayanan S
    Sci Adv; 2022 Feb; 8(7):eabj7002. PubMed ID: 35179953
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Taraxacum mongolicum extract inhibited malignant phenotype of triple-negative breast cancer cells in tumor-associated macrophages microenvironment through suppressing IL-10 / STAT3 / PD-L1 signaling pathways.
    Deng XX; Jiao YN; Hao HF; Xue D; Bai CC; Han SY
    J Ethnopharmacol; 2021 Jun; 274():113978. PubMed ID: 33716082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blockade of DC-SIGN
    Hu B; Wang Z; Zeng H; Qi Y; Chen Y; Wang T; Wang J; Chang Y; Bai Q; Xia Y; Wang Y; Liu L; Zhu Y; Dai B; Guo J; Xu L; Zhang W; Xu J
    Cancer Res; 2020 Apr; 80(8):1707-1719. PubMed ID: 32060149
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blockage of L2HGDH-mediated S-2HG catabolism orchestrates macrophage polarization to elicit antitumor immunity.
    Feng S; Wang D; Jin Y; Huang S; Liang T; Sun W; Du X; Zhuo L; Shan C; Zhang W; Jing T; Zhao S; Hong R; You L; Liu G; Chen L; Ye D; Li X; Yang Y
    Cell Rep; 2024 Jun; 43(6):114300. PubMed ID: 38829739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRD4 Inhibition by AZD5153 Promotes Antitumor Immunity via Depolarizing M2 Macrophages.
    Li X; Fu Y; Yang B; Guo E; Wu Y; Huang J; Zhang X; Xiao R; Li K; Wang B; Hu J; Sun C; Chen G
    Front Immunol; 2020; 11():89. PubMed ID: 32184777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reprogramming of PD-1+ M2-like tumor-associated macrophages with anti-PD-L1 and lenalidomide in cutaneous T cell lymphoma.
    Han Z; Wu X; Qin H; Yuan YC; Schmolze D; Su C; Zain J; Moyal L; Hodak E; Sanchez JF; Lee PP; Feng M; Rosen ST; Querfeld C
    JCI Insight; 2023 Jul; 8(13):. PubMed ID: 37427589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor microenvironment remodeling and tumor therapy based on M2-like tumor associated macrophage-targeting nano-complexes.
    Han S; Wang W; Wang S; Yang T; Zhang G; Wang D; Ju R; Lu Y; Wang H; Wang L
    Theranostics; 2021; 11(6):2892-2916. PubMed ID: 33456579
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.